{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:48:03Z","timestamp":1788580083570,"version":"build-2803163510"},"reference-count":130,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CA A Cancer J Clinicians"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Historical advances in the care of patients with non\u2010Hodgkin lymphoma (NHL) have been restricted largely to patients with B\u2010cell lymphoma. The peripheral T\u2010cell lymphomas (PTCLs), which are rare and heterogeneous in nature, have yet to experience the same degree of improvement in outcome over the past 20 to 30\u00a0years. It is estimated that there are approximately 80,000 and 14,000 cases, respectively, of NHL and Hodgkin lymphoma per year in the United States. As a subgroup of NHL, the PTCLs account for 6% to 10% of all cases of NHL, making them exceedingly rare. In addition, the World Health Organization 2017 classification describes 29 distinct subtypes of PTCL. This intrinsic diversity, coupled with its rarity, has stymied progress in the disease. In addition, most subtypes carry an inferior prognosis compared with their B\u2010cell counterparts, an outcome largely attributed to the fact that most treatment paradigms for patients with PTCL have been derived from B\u2010cell neoplasms, a radically different disease. In fact, the first drug ever approved for patients with PTCL was approved only a decade ago. The plethora of recent drug approvals in PTCL, coupled with a deeper understanding of the molecular pathogenesis of the disease, has stimulated the field to pursue new avenues of research that are now largely predicated on the development of novel, targeted small molecules, which include a host of epigenetic modifiers and biologics. There is an expectation these advances may begin to favorably challenge the chemotherapy paradigms that have been used in the T\u2010cell malignancies.<\/jats:p>","DOI":"10.3322\/caac.21589","type":"journal-article","created":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T08:10:52Z","timestamp":1575879052000},"page":"47-70","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["The rapidly changing landscape in mature T\u2010cell lymphoma (MTCL) biology and management"],"prefix":"10.3322","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6661-9119","authenticated-orcid":false,"given":"Enrica","family":"Marchi","sequence":"first","affiliation":[{"name":"Department of Medicine Center for Lymphoid Malignancies Columbia University Medical Center, College of Physicians and Surgeons New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen A.","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Department of Medicine Center for Lymphoid Malignancies Columbia University Medical Center, College of Physicians and Surgeons New York New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,12,9]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1281122"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.146571"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.331"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-755496"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.006"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1114885"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-435297"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.200"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000005570"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/PRS.0000000000005500"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0478-2"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-536359"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-017-0582-9"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2873"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3442"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182444"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-824607"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-391748"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1111708"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-10-531509"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2872"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10066"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-019-0230-6"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810069"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-408542"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-644948"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2916"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.01.001"},{"key":"e_1_2_7_31_1","volume-title":"Hematology. Basic Principles and Practice","author":"Silberstein L","year":"2018"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802455867"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5540"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_7_36_1","first-page":"54","article-title":"Breast implant\u2010associated anaplastic large cell lymphoma: what we know","volume":"10","author":"DePaola NEK","year":"2019","journal-title":"J Adv Pract Oncol."},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13954"},{"key":"e_1_2_7_38_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow SH","year":"2017"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-221275"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.255"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.91"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0028"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.157"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-1-20"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2012.00334"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2012.00322"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-09-3801"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-036368"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140987"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0507184102"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2012.12.001"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2005.12.011"},{"key":"e_1_2_7_53_1","volume-title":"GeneReviews","author":"Taylor AK","year":"1993"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.06.037"},{"key":"e_1_2_7_55_1","first-page":"76","article-title":"Prognostic significance of T\u2010cell phenotype in aggressive non\u2010Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)","volume":"92","author":"Gisselbrecht C","year":"1998","journal-title":"Blood."},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6327"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00533-1"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1459610"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-09-3080"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-310342"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf033"},{"key":"e_1_2_7_64_1","first-page":"3509","article-title":"Lymphomas expressing ALK fusion protein(s) other than NPM\u2010ALK","volume":"94","author":"Falini B","year":"1999","journal-title":"Blood."},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.8195"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199304083281404"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270785"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.167742"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20999"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32984-2"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512073332305"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.2719"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.4870"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31861"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.4628"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.7503"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.125"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh471"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404306"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00856.x"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn022"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp211"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu443"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.12.050"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705752"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.0188"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.574754"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705036"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08210.x"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.79"},{"key":"e_1_2_7_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21449"},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2603"},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.4207"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00067a020"},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000077124"},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06658.x"},{"key":"e_1_2_7_97_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8470"},{"key":"e_1_2_7_98_1","doi-asserted-by":"publisher","DOI":"10.2146\/news090080"},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_2_7_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4149.4149"},{"key":"e_1_2_7_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13340"},{"key":"e_1_2_7_102_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.779688"},{"issue":"1","key":"e_1_2_7_103_1","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1182\/blood.V130.Suppl_1.818.818","article-title":"Pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in previously untreated patients with peripheral T\u2010cell lymphoma (PTCL): a phase 1 dose\u2010escalation study [abstract]","volume":"130","author":"Shustov A","year":"2017","journal-title":"Blood."},{"key":"e_1_2_7_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07954.x"},{"key":"e_1_2_7_105_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-312603"},{"key":"e_1_2_7_106_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"e_1_2_7_107_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20070779"},{"key":"e_1_2_7_108_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13222"},{"key":"e_1_2_7_109_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.2782"},{"key":"e_1_2_7_110_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.85"},{"key":"e_1_2_7_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90361-S"},{"key":"e_1_2_7_112_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.8972"},{"key":"e_1_2_7_113_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07740.x"},{"key":"e_1_2_7_114_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_2_7_115_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.7285"},{"key":"e_1_2_7_116_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-840538"},{"key":"e_1_2_7_117_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802470"},{"key":"e_1_2_7_118_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.6327"},{"key":"e_1_2_7_119_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29103"},{"key":"e_1_2_7_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806737"},{"key":"e_1_2_7_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00097-6"},{"key":"e_1_2_7_122_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019001285"},{"key":"e_1_2_7_123_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.33.15_suppl.8521"},{"key":"e_1_2_7_124_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2991.2991"},{"key":"e_1_2_7_125_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2249"},{"key":"e_1_2_7_126_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13566"},{"issue":"1","key":"e_1_2_7_127_1","first-page":"1515","article-title":"A phase 1\/2 study of oral 5\u2010azacitidine and romidepsin in patients with lymphoid malignancies reveals promising activity in heavily pretreated peripheral T\u2010cell lymphoma (PTCL) [abstract]","volume":"130","author":"Falchi L","year":"2017","journal-title":"Blood."},{"key":"e_1_2_7_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.03.022"},{"issue":"1","key":"e_1_2_7_129_1","first-page":"1522","article-title":"A phase 1 study investigating the combination of AFM13 and the monoclonal anti\u2010PD\u20101 antibody pembrolizumab in patients with relapsed\/refractory Hodgkin lymphoma after brentuximab vedotin failure: data from the dose escalation part of the study [abstract]","volume":"130","author":"Ansell SM","year":"2017","journal-title":"Blood."},{"key":"e_1_2_7_130_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.1812.1812"},{"key":"e_1_2_7_131_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.123_2630"}],"container-title":["CA: A Cancer Journal for Clinicians"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.3322%2Fcaac.21589","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.3322\/caac.21589","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.3322\/caac.21589","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.3322\/caac.21589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:44:47Z","timestamp":1762332287000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.3322\/caac.21589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,9]]},"references-count":130,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.3322\/caac.21589"],"URL":"https:\/\/doi.org\/10.3322\/caac.21589","archive":["Portico"],"relation":{},"ISSN":["0007-9235","1542-4863"],"issn-type":[{"value":"0007-9235","type":"print"},{"value":"1542-4863","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,9]]},"assertion":[{"value":"2019-07-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-12-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}